Echo IQ has taken a major step in its US expansion by deploying its AI-powered EchoSolv AS software at Mount Sinai Health System, one of America’s leading cardiovascular centres. This marks a key milestone in integrating AI into routine cardiology workflows at scale.
- EchoSolv AS deployed at Mount Sinai Health System in New York
- Mount Sinai Fuster Heart Hospital ranks No. 2 nationally for cardiology
- Deployment advances Echo IQ’s US commercial strategy
- Partnership supports future research and product development
- Echo IQ continues talks with other US hospitals
Strategic Deployment at a Leading Cardiovascular Institution
Echo IQ (ASX:EIQ) has secured a significant foothold in the US healthcare market by deploying its AI-based EchoSolv AS decision support software at Mount Sinai Health System in New York. This system, noted for its scale and clinical excellence, includes seven hospitals and over 3,760 beds, with the Mount Sinai Fuster Heart Hospital ranked No. 1 in New York and No. 2 nationally for cardiology and heart surgery in the U.S. News & World Report’s 2025–26 rankings. The deployment represents a milestone in Echo IQ’s ambition to embed AI tools within high-volume, complex cardiovascular programs.
Mount Sinai’s large echocardiography footprint and its commitment to clinical innovation provide a fertile environment for EchoSolv AS, which assists physicians in assessing severe aortic stenosis more consistently. The system’s integration into Mount Sinai’s workflows underscores growing acceptance of AI as a practical adjunct in cardiology diagnostics.
Commercial Growth and Research Opportunities
Nick Lubbers, Echo IQ’s US President and General Manager, highlighted the deployment as a pivotal step in the company’s US commercial growth trajectory. He emphasised that EchoSolv AS offers a "measurement-based second look" to support cardiologists, reflecting a broader strategy to expand partnerships with leading hospitals. This approach aims not only to build commercial traction but also to open avenues for future research and product development.
Dr Stamatios Lerakis, Director of Cardiovascular Imaging at Mount Sinai, praised EchoSolv AS for its potential to identify under-diagnosed aortic stenosis cases, which may otherwise miss out on therapeutic advances. He described the software as a valuable adjunct that strengthens patient care without replacing physician judgment.
Echo IQ’s Expanding US Footprint
This deployment complements Echo IQ’s ongoing US commercial efforts, including its recent expanded agreement with Mayo Clinic for the EchoSolv HF heart failure diagnostic tool, pending FDA clearance. Echo IQ’s US market entry has been progressing through clinical validation and regulatory submissions, with the Mayo Clinic partnership providing access to a network of over 80 hospitals. These developments signal a concerted push to scale AI-enabled decision support across major cardiovascular centres. Echo IQ continues to engage with other prospective US hospitals to broaden EchoSolv AS adoption.
While Echo IQ’s revenue growth and expanding partnerships are promising, the company remains subject to regulatory and commercial risks, including FDA clearance maintenance, integration challenges, and competitive pressures. The Mount Sinai deployment will serve as a critical test case for real-world clinical utility and scalability of AI in cardiology.
Bottom Line?
Mount Sinai’s adoption of EchoSolv AS is a tangible step forward for Echo IQ’s US ambitions, but translating this into widespread market penetration will require sustained clinical validation and regulatory success.
Questions in the middle?
- How will Echo IQ leverage the Mount Sinai deployment to accelerate uptake at other US hospitals?
- What impact will FDA clearance outcomes have on EchoSolv AS’s commercial momentum?
- Can Echo IQ translate clinical validation into durable revenue growth amid competitive AI cardiology tools?